Abstract

Sin Nombre virus (SNV) causes hantavirus cardiopulmonary pulmonary syndrome (HCPS) with the loss of pulmonary vascular endothelial integrity, and pulmonary edema without causing cytopathic effects on the vascular endothelium. HCPS is associated primarily with a dysregulated immune response. We previously found occult signs of hemostatic imbalance in the form of a sharp >30–100 fold increase in the expression of plasminogen activator inhibitor type 1 (PAI-1), in serial blood plasma draws of terminal stage-patients. However, the mechanism of the increase in PAI-1 remains unclear. PAI-1 is a primary inhibitor of fibrinolysis caused by tissue plasminogen activator (tPA) and urokinase plasminogen activator plasma (uPA). Here, we investigate factors that contribute to PAI-1 upregulation during HCPS. Using zymography, we found evidence of PAI-1-refractory uPA activity and no tPA activity in plasma samples drawn from HCPS patients. The sole prevalence of uPA activity suggested that severe inflammation drove PAI-1 activity. We have recently reported that the P2Y2 receptor (P2Y2R) mediates SNV infectivity by interacting in cis with β3 integrins, which activates the latter during infection. P2Y2R is a known effector for several biological processes relevant to HCPS pathogenesis, such as upregulation of tissue factor (TF), a primary initiator of the coagulation cascade, stimulating vascular permeability and leukocyte homing to sites of infection. As P2Y2R is prone to upregulation under conditions of inflammation, we compared the expression level of P2Y2R in formalin fixed tissues of HCPS decedents using a TaqMan assay and immunohistochemistry. Our TaqMan results show that the expression of P2Y2R is upregulated significantly in HCPS cases compared to non- HCPS controls (P < 0.001). Immunohistochemistry showed that lung macrophages were the primary reservoir of high and coincident localization of P2Y2R, uPA, PAI-1, and TF antigens. We also observed increased staining for SNV antigens in the same tissue segments where P2Y2R expression was upregulated. Conversely, sections of low P2Y2R expression showed weak manifestations of macrophages, SNV, PAI-1, and TF. Coincident localization of P2Y2R and PAI-1 on macrophage deposits suggests an inflammation-dependent mechanism of increasing pro-coagulant activity in HCPS in the absence of tissue injury.

Highlights

  • Sin Nombre virus (SNV) causes a severe form of hantavirus cardiopulmonary syndrome (HCPS), with case fatality rates of 30–40%

  • Using formalin-fixed, paraffin embedded (FFPE) autopsy tissues from 22 HCPS decedents we obtained from the State of New Mexico Office of the Medical Investigator (OMI), we studied the expression of P2Y2 receptor (P2Y2R) relative to non-HCPS control samples using TaqMan and immunohistochemistry

  • We showed that plasminogen activator inhibitor type 1 (PAI-1) increased dramatically at the onset of stage III HCPS by rising more than 100-fold above average levels compared to the mild class I and severe class II cases (5-fold increase, on average) (Bondu et al, 2015)

Read more

Summary

Introduction

Sin Nombre virus (SNV) causes a severe form of hantavirus cardiopulmonary syndrome (HCPS), with case fatality rates of 30–40%. SNV has a particular tropism for vascular endothelial cells in humans, which the virus infects without causing any visible cytopathic effects, yet causes the loss of endothelial cell barrier function (Nolte et al, 1995; Hjelle and Torres-Perez, 2010; Vaheri et al, 2013; Hjelle, 2014; Safronetz et al, 2014). Laboratory findings have revealed the occurrence of disseminated intravascular coagulopathy (DIC) in HCPS patients in the absence of clinical signs of bleeding, intravascular thrombosis and apparent damage to the vascular endothelium (Nolte et al, 1995; Zaki et al, 1995). The cause for PAI-1 upregulation in this setting is not yet understood

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call